1. Introduction {#sec1}
===============

China is one of the fastest developing countries in the world. Since embracing market reforms in 1979, the country has experienced unequaled economic growth and has sustained an average of GDP growth of over eight percent for nearly three decades. Meanwhile, increased global trade and advances in agriculture have led to food surpluses in a country previously plagued by severe cyclical famine. This, coupled with improvements in sanitation and immunization, has dramatically raised average life expectancy from 46.6 years in 1960 to 73.1 years in 2009 \[[@B1]\]. Increased longevity, urbanization, and changes in traditional diets have resulted in an epidemic of cardiovascular disease (CVD). Today, CVD is the leading cause of both morbidity and mortality in China, responsible for one-third of all annual deaths \[[@B1], [@B2]\]. The increased burden of CVD can be attributed, in part, to the rapid rise in risk factors hypertension, smoking, obesity, diabetes mellitus, and metabolic syndrome. Considerable attention has already been given to both smoking and hypertension. However, while the prevalence of smoking remains high, its incidence peaked in the mid 1990s, and currently it is expected to decline over the next three decades \[[@B4]\]. In the meantime, rates of obesity, diabetes, and metabolic syndrome are projected to rise considerably. These cardiometabolic risk factors will play an increasingly important role in the rising CVD epidemic in China and deserve special attention.

2. Obesity {#sec2}
==========

Obesity is an excess of body fat, defined in western populations by Body Mass Index \>30 kg/m^2^ \[[@B5]\]. It is a known risk factor for the development of atherosclerotic cardiovascular disease, type 2 diabetes, dyslipidemia, and hypertension \[[@B6]\]. There is a growing body of evidence that demonstrate for any given BMI Asians have a greater percentage of body fat and a higher cardiovascular risk \[[@B9], [@B7]--[@B10]\]. In addition, Chinese people are more likely to develop central obesity, which has been associated with a higher risk of developing cardiovascular disease \[[@B11]\]. Based on these studies, the Working Group on Obesity in China recommended a BMI cutoff of 24 kg/m^2^ and 28 kg/m^2^, for overweight and obesity, respectively \[[@B12]\]. The Chinese Ministry of Health has incorporated these cutoffs in guidelines to prevent and control overweight and obesity in Chinese adults \[[@B12]\].

Rapid economic development and industrialization have led to changes in traditional diets and increasingly sedentary lifestyles \[[@B13], [@B14]\]. China, once considered one of the leanest populations in the world, has experienced rapidly escalating rates of overweight and obesity. A recent meta-analysis of nationally representative data by Wang \[[@B15]\] estimated that the prevalence of overweight and obesity rose 49.5 percent between 1992 and 2002, from 20.0 to 29.9 percent (using the WGOC cutoff for overweight and obesity) ([Table 1](#tab1){ref-type="table"}). The rise has been greatest in urban high-income populations, such as Beijing. Similar rates have been found in other studies \[[@B16], [@B17]\], translating into an estimated 401 million overweight or obese Chinese.

In 2003, the total medical cost attributable to overweight and obesity was estimated at 2.6 billion USD, or 3.7 percent of total national medical costs \[[@B18]\]. The prevalence of overweight and obesity and it\'s economic burden on the Chinese healthcare system will only increase as greater numbers of rural Chinese move into the ranks of the urban middle class.

3. Diabetes {#sec3}
===========

Changes in diet and lifestyle have also led to a tremendous increase in the number of Chinese with obesity-related type 2 diabetes mellitus (T2DM). Diabetes is a major risk factor for cardiovascular disease and its prevalence has increased dramatically in the past two decades. In 1994, the prevalence of DM and IGT among individuals between 25 and 64 years was estimated to be 2.6 percent and 3.2 percent, respectively \[[@B19]\]. By 2001, the prevalence of diabetes and IGT had increased to 5.49 percent and 7.33 percent, respectively \[[@B20]\]. In 2008, the prevalence of diabetes and IGT in Chinese \>20 years old had risen to 9.7 percent and 15.5 percent, respectively \[[@B21]\], ([Figure 1](#fig1){ref-type="fig"}).

Alarmingly, the prevalence of diabetes in China has nearly quadrupled over the last 15 years. Although the prevalence of DM and IGT remain lower than that of other industrialized nations, such as the USA, China\'s enormous population, estimated to be over 1.3 billion, makes it home to the largest diabetic population in the world. Today, there are 92.4 million Chinese suffering from diabetes, with an additional 148.2 million living with impaired glucose tolerance \[[@B21]\].

Despite the increasing prevalence of diabetes in China, rates of awareness, treatment, and control remain low. In 2000, a nationally representative study of 15,236 Chinese adults found that nearly 75 percent of diabetics were unaware of their diagnosis \[[@B22]\]. Of those that were aware, only 20 percent were taking prescribed medications or pursuing nonpharmacological interventions (exercise or dietary modification), of these, only 8.3 percent managed to achieve glycemic control \[[@B22]\] ([Table 2](#tab2){ref-type="table"}). Similar rates of awareness were reported by Yang et al., 2010 \[[@B21]\]. Based on these estimates, there are currently 84.7 million Chinese with *uncontrolled* diabetes mellitus. They are at increased risk for developing long-term complications including cardiovascular disease, renal disease, peripheral neuropathy, retinopathy, and blindness. In 2007, the direct medical costs of obesity-related DM and its complication were estimated to be 26 billion USD, representing 16 percent of all Chinese medical expenditures. If current trends continue, this cost is projected to increase to 47.2 billion USD by 2030 \[[@B23]\].

4. Metabolic Syndrome {#sec4}
=====================

The metabolic syndrome (MetS) is a combination of interconnected risk factors for obesity, insulin resistance and glucose intolerance, dyslipidemia, and hypertension. The adult treatment panel III of the National Cholesterol Education Program (NCEP) defined a group of five clinical criteria for effective classification of MetS ([Table 3](#tab3){ref-type="table"}).

An individual that meets three or more of these criteria can be given the clinical diagnosis of MetS. The syndrome is associated with the development of diabetes, cardiovascular, and kidney disease, and an increased risk for mortality \[[@B24], [@B25]\]. Based on the NCEP classification, a rapidly growing epidemic of metabolic syndrome is taking place in China. In 1992, the prevalence of metabolic syndrome in China was 13.3 percent, 12.7 percent in males and 14.2 percent in females \[[@B26]\]. By 2000, the prevalence of metabolic syndrome had increased to 15.1 percent, 13.6 percent in men and 16.6 percent in women \[[@B27]\]. This prevalence rate was determined using the modified Asian criteria for waist circumference, based on studies which have shown that Asians suffer from the same risk of cardiovascular disease development at smaller waist circumferences, 90 cm for men and 80 cm for women \[[@B28], [@B29]\]. In 2000, 64 million Chinese had metabolic syndrome, this number increases to 71 million using the modified ATP III criteria for Asian populations \[[@B30]\].

Numerous studies have shown that the prevalence of metabolic syndrome increases with age \[[@B30]--[@B32]\]. This finding has important implications for China, whose enormous population is aging rapidly as an unintended consequence of the "one child policy" adopted by the government in 1978. The population of Chinese seniors grows by 3.3 percent annually. By 2050, 30 percent of the population will be over the age of 65 years \[[@B33]\]. The increasing prevalence of MetS among elderly Chinese was demonstrated in a Hong Kong-based population study by Thomas \[[@B34]\]. Of participants aged 25--29 years, only 3.1 percent had MetS, compared to 41.0 percent of those aged over 70 years. The age- and gender-adjusted prevalence was 21.2 percent. This approaches prevalence rates found in other industrialized nations \[[@B35], [@B36]\]. The high prevalence of MetS among Hong Kong Chinese forewarns a rapidly increasing problem in Mainland, China. Hong Kong, with its vibrant economy fostered by decades of British occupation has already gone through the rapid socioeconomic changes the rest of the country is currently experiencing. In addition, the rapid influx of rural Chinese into the country\'s overcrowded megacities will only accelerate the rapid rise in MetS and related complications \[[@B37]\], ([Figure 2](#fig2){ref-type="fig"}).

5. Conclusion {#sec5}
=============

China is a middle-income country in rapid economic and epidemiologic transition. Decades of economic development have led to dramatic changes in life expectancy, lifestyle, and diet. An older more sedentary population finds itself increasingly more burdened by diseases of its newfound wealth obesity, diabetes, and metabolic syndrome, which already approach those found in industrialized nation in both Europe and the USA. The increasing prevalence of cardiometabolic risk factors has resulted in an unprecedented rise in the incidence of cardiovascular disease. The incidence of CVD is predicted to rise by at least 50% in the next 20 years, with an additional 23 percent increase resulting from trends in cardiometabolic risk factors \[[@B38]\]. Perhaps even more alarming, Chinese are less likely to be diagnosed and less likely to gain control of their chronic disease \[[@B22], [@B39]\] and have limited access to quality healthcare services \[[@B40], [@B41]\]. Furthermore, the Chinese healthcare system, with its historical focus on treating infectious diseases, is ill equipped to handle the rising epidemic of cardiovascular disease \[[@B42]\]. The Chinese have proven themselves capable of rapid large-scale socioeconomic change. However, the ability of the government to respond and control such an epidemic will depend on whether or not it approaches the task with the same vigor it has approached economic development. While China can benefit from the rich body of existing research on cardiometabolic disease, more studies on Chinese-specific risk factors are needed.

This paper is based on a thesis submitted in partial fulfillment of the requirements for the degree of Masters in public health in the department of Global Health and Population, School of Public Health, at the Harvard University, in June, 2009.
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###### 

Obesity trends 1992--2002 \[[@B16]\].

  Classification BMI Kg/m^2^   Prevalence (%)   Percent change 1992--2002   Estimated number of overweight & obese chinese\*   
  ---------------------------- ---------------- --------------------------- -------------------------------------------------- -------------
  Overweight 24.0--27.9        16.4             22.8                        39.0%                                              305,748,000
  Obese \> 28.0                3.6              7.1                         97.2%                                              95,211,000

Adapted from \[[@B15]\].

\*Based on a population statistics reported by the Chinese Bureau of Statistics, 2011.

###### 

Awareness, treatment, and control of diabetes in Chinese^t^.

  Population   Awareness   Treatment   Control
  ------------ ----------- ----------- ---------
  China        23.7%       4.81%       0.40%

^t^Percentage of total diabetics.

Adapted from \[[@B22]\].

###### 

NCEP ATP III diagnostic criteria for metabolic syndrome \[[@B43]--[@B45]\].

  Criteria                                                    Category
  ----------------------------------------------------------- -------------------------------------------------------------------
  Elevated fasting glucose                                    ≥110 mg/dL or use of antidiabetic medications±
  Elevated triglycerides                                      ≥150 mg/dL
  Reduced HDLC                                                \<40 mg/dL in men\<50 mg/dL in women
  Elevated blood pressure                                     ≥130 mm Hg or ≥85 mm Hg DBP or use of antihypertensive medication
  Elevated waist circumference                                \>102 cm in men\>88 cm in women
                                                              
  WHO modified Asian waist circumference criteria \[[@B9]\]   
                                                              
  Elevated waist circumference                                \>90 cm in men\>80 cm in women

±WHO classifies fasting blood glucose \>100 mg/dL as elevated.

Adapted from \[[@B46]--[@B48]\].
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